The U.S. Food and Drug Administration on Friday approved the first hepatitis C virus (HCV) polymerase inhibitor, sofosbuvir, to be marketed by Gilead Sciences under the brand name Sovaldi. Sofosbuvir was approved for use with ribavirin for people with HCV genotypes 2 or 3 -- making it the first-ever interferon-free hepatitis C treatment -- and in combination with pegylated interferon/ribavirin for people with harder-to-treat HCV genotypes 1 or 4.
A standing-room-only crowd packed the house at Magnet in San Francisco's Castro district on December 3 for a Real Talk discussion about condomless sex and HIV prevention. A panel of community members and medical experts considered questions such as: Why do gay and bisexual men have condom-free sex? Are community attitudes around condom use changing? and How do treatment as prevention and pre-exposure prophylaxis (PrEP) factor into the equation?
The final day of AASLD Liver Meeting, recently held in Washington, DC, featured an overview of the status of new hepatitis C therapies, similarities between HCV and HIV, and a look towards the future of hepatitis C treatment. The development of next-generation HCV drugs has been remarkably rapid and experts agree that it may soon be possible to cure all patients with hepatitis C, but access is likely to be a challenge.
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.